Akebia Therapeutics
AKBA
79 hedge funds and large institutions have $46M invested in Akebia Therapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 8 closing their positions.
431% more call options, than puts
Call options by funds: $849K | Put options by funds: $160K
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
49% more capital invested
Capital invested by funds: $30.9M → $46M (+$15.1M)
22% more funds holding
Funds holding: 65 → 79 (+14)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.17% less ownership
Funds ownership: 28.21% → 27.05% (-1.2%)
45% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.06M |
| 2 |
Renaissance Technologies
New York
|
+$958K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$421K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$390K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$328K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.54M |
| 2 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$1.83M |
| 3 |
Morgan Stanley
New York
|
-$260K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$109K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$94.7K |
AKBA Hedge Fund Activity: Q2 2023 in Review
79 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2023, worth a combined $46M — up 49% from $30.9M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AKBA positions and 8 closed out — a net gain of 14 holders — while 11 added to existing stakes and 20 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.06M. The largest seller was Vanguard Group, cutting an estimated $4.54M.
- 79 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2023, up from 65 in Q1 2023.
- Funds reported $46M of Akebia Therapeutics stock for Q2 2023, up 49% quarter-over-quarter.
- 22 funds opened new Akebia Therapeutics positions in Q2 2023 and 8 closed out, a net change of +14 holders.
- The largest Akebia Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $1.06M added.
- The largest Akebia Therapeutics seller in Q2 2023 was Vanguard Group, an estimated $4.54M sold.
Based on aggregated 13F filings for Q2 2023.